关于：前列腺特异性抗原：一种被滥用和诋毁的前列腺癌生物标志物。 - Suppr

Suppr

超能文献

Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

作者信息

Hamilton Robert J, Platz Elizabeth A, Freedland Stephen J

出版信息

J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7.

DOI:10.1093/jnci/djp043

PMID:19351913

Abstract

摘要

相似文献

Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7.

Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

J Natl Cancer Inst. 2008 Nov 5;100(21):1487-8. doi: 10.1093/jnci/djn368. Epub 2008 Oct 28.

Re: The influence of statin medications on prostate-specific antigen levels.

J Natl Cancer Inst. 2009 Apr 15;101(8):610; author reply 610-1. doi: 10.1093/jnci/djp042. Epub 2009 Apr 7.

The influence of statin medications on prostate-specific antigen levels.

J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362. Epub 2008 Oct 28.

Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26.

Is an improved PSA screening test in sight?

J Natl Cancer Inst. 2007 Oct 17;99(20):1503-4. doi: 10.1093/jnci/djm195. Epub 2007 Oct 9.

Application of prostate-specific antigen in prostate cancer.

MLO Med Lab Obs. 2008 Oct;40(10):54, 56-7.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.

Is screening for prostate cancer the current gold standard?--"yes".

Eur J Cancer. 1997 Mar;33(3):354-6.

The cautionary tale of PSA testing.

Arch Intern Med. 2010 Jul 26;170(14):1262-3. doi: 10.1001/archinternmed.2010.222.

引用本文的文献

The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.

PLoS One. 2014 Sep 18;9(9):e107234. doi: 10.1371/journal.pone.0107234. eCollection 2014.

Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.

PLoS One. 2012;7(11):e48889. doi: 10.1371/journal.pone.0048889. Epub 2012 Nov 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7.

Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

J Natl Cancer Inst. 2008 Nov 5;100(21):1487-8. doi: 10.1093/jnci/djn368. Epub 2008 Oct 28.

Re: The influence of statin medications on prostate-specific antigen levels.

J Natl Cancer Inst. 2009 Apr 15;101(8):610; author reply 610-1. doi: 10.1093/jnci/djp042. Epub 2009 Apr 7.

The influence of statin medications on prostate-specific antigen levels.

J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362. Epub 2008 Oct 28.

Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26.

Is an improved PSA screening test in sight?

J Natl Cancer Inst. 2007 Oct 17;99(20):1503-4. doi: 10.1093/jnci/djm195. Epub 2007 Oct 9.

Application of prostate-specific antigen in prostate cancer.

MLO Med Lab Obs. 2008 Oct;40(10):54, 56-7.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.

Is screening for prostate cancer the current gold standard?--"yes".

Eur J Cancer. 1997 Mar;33(3):354-6.

The cautionary tale of PSA testing.

Arch Intern Med. 2010 Jul 26;170(14):1262-3. doi: 10.1001/archinternmed.2010.222.

引用本文的文献

The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.

PLoS One. 2014 Sep 18;9(9):e107234. doi: 10.1371/journal.pone.0107234. eCollection 2014.

Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.

PLoS One. 2012;7(11):e48889. doi: 10.1371/journal.pone.0048889. Epub 2012 Nov 12.